Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Where the cash went Twelve months to Sep 30, 2026
Free cash flow of $19.7B covered $11.8B of dividends and buybacks. Cash fell by $4.9B. Lines the picture does not name came to −$8.8B. What is a cash flow statement?
- Free cash flow
- $19.7B 64.2% of operating cash flow
- Returned to shareholders
- $11.8B 60.1% of free cash flow
- Debt, net
- $7.3B borrowed
- Change in cash
- −$4.9B over the period
| Operating cash flow | 30.6 |
|---|---|
| Capital expenditures | −11.0 |
| Free cash flow | 19.7 |
| Acquisitions, net | −11.2 |
| Dividends | −6.0 |
| Buybacks, net | −5.8 |
| Debt raised, net | +7.3 |
| Other | −8.8 |
| Change in cash | −4.9 |
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $16.8B | $20.5B | $28.1B | $30.6B |
| Capex | −$7.8B | −$8.7B | −$9.9B | −$11.0B |
| Free cash flow | $9.0B | $11.8B | $18.2B | $19.7B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more TTM periods Free account |
20,640.00 | 25,277.00 | 26,711.00 | 27,580.00 |
Depreciation & Amortization |
1,997.00 | 2,043.00 | 2,099.00 | 2,174.00 | |
Non Cash Items (Other) |
2,269.00 | (447.00) | 4,953.00 | 9,882.00 | |
Accounts Receivable Change |
(11,905.60) | — | — | — | |
Change in inventories |
(9,202.70) | — | — | — | |
Accounts Payable Change |
18,762.00 | — | — | — | |
Change in other assets and liabilities |
(6,609.00) | (4,909.00) | (4,196.00) | (7,507.00) | |
Operating Cash Flow |
16,813.00 | 20,480.00 | 28,083.00 | 30,645.00 | |
Capital expenditures |
(7,841.00) | (8,657.00) | (9,893.00) | (10,984.00) | |
Net Aquisitions |
— | (1,607.40) | (10,354.40) | (11,241.40) | |
Short Term Investments Change (Net) |
— | — | (882.90) | — | |
Long-Term Investments Change (Net) |
1,059.00 | 959.00 | — | — | |
Other investing activities |
(3,450.00) | (2,039.00) | (5,482.00) | (9,262.00) | |
Investing cash flow |
(10,972.00) | (11,535.00) | (25,097.00) | (30,414.00) | |
Repayment/Issuance of Debt (Net) |
8,051.00 | 4,464.00 | 15,216.00 | 7,318.00 | |
Equity Repurchase (Common, Net) |
(4,108.00) | (5,264.00) | (6,173.00) | (5,842.00) | |
Dividends Paid (Total) |
(5,384.00) | (5,586.00) | (5,785.00) | (5,980.00) | |
Other financial activities |
(772.00) | (677.00) | (650.00) | (638.00) | |
Financing cash flow |
(2,213.00) | (7,063.00) | 2,608.00 | (5,142.00) | |
Exchange Rate Adjustment |
372.00 | 307.00 | (20.00) | 4.00 | |
Change in Cash |
4,000.00 | 2,189.00 | 5,574.00 | (4,907.00) | |
Beginning Cash |
3,268.00 | 7,268.00 | 7,268.00 | 7,268.00 | |
Ending Cash |
7,268.00 | 9,457.00 | 12,842.00 | 2,361.00 | |
Stock Based Compensation |
626.00 | 633.00 | 649.00 | 698.00 | |
Dividends Paid (Common) |
(5,384.00) | (5,586.00) | (5,785.00) | (5,980.00) | |
Assets Liabilities Change (Total) |
(8,093.00) | (6,393.00) | (5,680.00) | (8,991.00) | |
Investments Change (Net) |
319.00 | 219.00 | 83.00 | (25.00) | |
Issuance/Purchase of Shares |
(4,108.00) | (5,264.00) | (6,173.00) | (5,842.00) |